HIV cannot be fully cured at an early stage, even with immediate treatment. The virus establishes hidden reservoirs inside long-lived immune cells during the very first days of infection, possibly before it even shows up in the bloodstream. Once those reservoirs form, no currently available treatment can completely eliminate them. That said, early action dramatically changes the outcome. Acting within hours can prevent infection entirely, and starting treatment during the acute phase keeps the virus suppressed, preserves the immune system, and shrinks those hidden reservoirs to their smallest possible size.
Why Early Treatment Can’t Fully Eliminate HIV
HIV works fast. Within days of entering the body, the virus inserts its genetic code into certain immune cells and goes dormant inside them. These sleeping copies, often called latent reservoirs, hide in long-lived cells throughout the body. Because the virus isn’t actively replicating in those cells, medications designed to block viral replication can’t reach or destroy it. Research confirms that latent reservoirs are established during the acute phase of infection, possibly before the virus is even detectable in the blood.
Even in animal studies where treatment began just three days after infection, the viral reservoir still formed in tissues. Starting treatment extremely early made the reservoir smaller, but it didn’t prevent it from forming at all. This is the core biological barrier to a cure: once HIV integrates into your DNA, standard medications can suppress it but not erase it.
The 72-Hour Window That Can Prevent Infection
There is one scenario where early action can stop HIV before it takes hold. Post-exposure prophylaxis (PEP) is a course of antiretroviral medication taken after a potential exposure. It works by blocking the virus from establishing itself permanently, but timing is everything.
A three-drug PEP regimen will almost certainly prevent infection if started within 48 hours of exposure. After 48 hours and up to 72 hours, effectiveness drops steeply regardless of how many drugs are used. A two-drug regimen is likely effective only within the first 24 hours. In one large program in China, 539 people who started PEP within 72 hours had zero infections. PEP is a 28-day course of medication, and it must be completed fully to work. After 72 hours, PEP is generally not recommended because the virus has likely already begun integrating into cells.
What Early Treatment Actually Achieves
If PEP isn’t an option and infection has occurred, starting antiretroviral therapy (ART) during the acute stage offers major advantages. The acute stage typically develops two to four weeks after infection, when many people experience flu-like symptoms including fever, headache, and rash. HIV is multiplying rapidly during this window, attacking and destroying CD4 immune cells throughout the body.
Beginning treatment during this phase does several important things. It rapidly lowers the amount of virus in the blood, shortens the period of active viral replication, and limits how many cells the virus can hide in long-term. Research on children treated very early found that each month of delay in starting treatment was associated with a 13% increase in the amount of HIV DNA stored in cells. Starting younger and sooner consistently produced smaller reservoirs.
With consistent treatment, most people reach what’s called an undetectable viral load, meaning the virus is suppressed to levels so low that standard tests can’t find it. At undetectable levels, HIV cannot be transmitted sexually, a principle known as U=U (undetectable equals untransmittable). People on effective ART have near-normal life expectancies.
The Mississippi Baby: What Happened When Treatment Started at 30 Hours
One of the most closely watched cases in HIV research involved a baby born in Mississippi in 2010 to a mother with undiagnosed HIV. Because of the high risk of infection, doctors started triple-drug antiretroviral treatment when the infant was just 30 hours old. Testing confirmed within days that the baby was infected.
The child stayed on treatment until 18 months of age, then was lost to follow-up and stopped taking medication. When doctors saw the child again five months later, something remarkable had happened: blood tests showed no detectable HIV and no HIV-specific antibodies. The child remained free of detectable virus for more than two years without any medication.
Then, at nearly four years old, the virus came back. A routine visit revealed 16,750 copies of HIV per milliliter of blood. As Anthony Fauci noted at the time, early treatment didn’t completely eliminate the reservoir of infected cells but “may have considerably limited its development.” Normally, HIV rebounds within weeks of stopping treatment, not years. The case demonstrated both the power and the limits of very early intervention: it shrank the reservoir dramatically, but it couldn’t eliminate it.
Detecting HIV as Early as Possible
Catching HIV early requires the right test. Standard antibody tests, including most rapid tests and home self-tests, can take 23 to 90 days after exposure to detect infection. That’s because the body needs time to produce antibodies.
A nucleic acid test (NAT) looks directly for the virus’s genetic material and can detect HIV as early as 10 to 33 days after exposure. If you’ve had a recent high-risk exposure and are within that early window, a NAT is the most reliable option. During the acute phase, many people experience symptoms that are easy to dismiss as the flu: fever, headache, rash, sore throat, and muscle aches appearing two to four weeks after exposure. These symptoms alone aren’t diagnostic, but they’re a reason to get tested if there’s been a recent risk.
The Few People Who Have Been Cured
True HIV cures do exist, but only through a procedure too dangerous and complex to serve as a general treatment. Seven people have been reportedly cured of HIV after receiving stem cell transplants for blood cancers. Most of these transplants came from donors who carried two copies of a rare genetic mutation that disables CCR5, a protein on the surface of immune cells that HIV uses as a doorway to enter. Without that doorway, the new immune system is essentially resistant to HIV.
A recent case published in Nature expanded what scientists thought was possible. A patient known as B2 achieved durable HIV remission after a transplant from a donor with only one copy of the mutation, meaning the new immune cells still had functional CCR5 receptors. B2 has maintained remission longer than most other cured patients, demonstrating that complete genetic resistance to HIV may not be strictly necessary for a cure. Three of the seven cured individuals received transplants from donors with just one copy of the mutation.
Stem cell transplants carry significant risks of serious complications and death, so they’re only performed when someone also has a life-threatening cancer that requires one. They are not a viable cure strategy for the broader population of people living with HIV.
Gene Editing and What’s Being Tested Now
The most promising avenue toward a broader cure involves gene editing technology that could replicate what stem cell transplants achieve, without the transplant itself. CRISPR-based therapies aim to edit the CCR5 gene directly in a person’s own cells, disabling the entry point HIV depends on. Early-phase clinical trials are underway. One trial assessed CRISPR editing of stem cells in a patient with both HIV and blood cancer, demonstrating that the approach is feasible and safe.
These trials are still in their earliest stages, testing safety rather than proving a cure. Translating gene editing into a practical, scalable HIV cure remains years away, with major challenges around editing enough cells throughout the body to make a difference.